Publications by authors named "W Fokkink"
Background And Objective: Intravenous immunoglobulin (IVIg) at a standard dosage is the treatment of choice for Guillain-Barré syndrome. The pharmacokinetics, however, is highly variable between patients, and a rapid clearance of IVIg is associated with poor recovery. We aimed to develop a model to predict the pharmacokinetics of a standard 5-day IVIg course (0.
View Article and Find Full Text PDFArticle Synopsis
- Researchers found a new way to measure a treatment called IVIg, which helps some sick patients, by using special tests that look for specific types of antibodies in their blood.
- This method was able to detect very small amounts of IVIg in patients, especially those with a condition called Guillain-Barré syndrome.
- The tests could show differences in how the body clears out the treatment compared to regular antibodies, which means they can help doctors understand how well IVIg is working for different patients.
Background And Purpose: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a clinical and electrophysiological heterogeneous immune-mediated polyneuropathy. Intravenous immunoglobulin (IVIg), corticosteroids, and plasma exchange are proven effective treatments for CIDP. The clinical response to IVIg is variable between patients and currently unexplained.
View Article and Find Full Text PDFBackground And Purpose: High peak serum immunoglobulin G (IgG) levels may not be needed for maintenance intravenous immunoglobulin (IVIg) treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and such high levels may cause side effects. More frequent lower dosing may lead to more stable IgG levels and higher trough levels, which might improve efficacy. The aim of this trial is to investigate whether high frequent low dosage IVIg treatment is more effective than low frequent high dosage IVIg treatment.
View Article and Find Full Text PDF